NeuroOne Medical Technologies (NMTC) Projected to Post Earnings on Tuesday

NeuroOne Medical Technologies (NASDAQ:NMTC) is projected to release its Q2 2026 results before the market opens on Tuesday, May 12th. Analysts expect NeuroOne Medical Technologies to post earnings of ($0.2267) per share and revenue of $2.5780 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its quarterly earnings results on Tuesday, February 17th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.06. NeuroOne Medical Technologies had a negative return on equity of 119.92% and a negative net margin of 78.34%.The company had revenue of $2.89 million for the quarter, compared to analysts’ expectations of $2.47 million. On average, analysts expect NeuroOne Medical Technologies to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NeuroOne Medical Technologies Stock Up 1.3%

NeuroOne Medical Technologies stock traded up $0.06 during midday trading on Tuesday, reaching $4.55. The company’s stock had a trading volume of 2,016 shares, compared to its average volume of 43,938. NeuroOne Medical Technologies has a fifty-two week low of $3.27 and a fifty-two week high of $6.96. The company has a market cap of $38.32 million, a P/E ratio of -4.46 and a beta of 0.60. The business has a 50-day simple moving average of $4.51 and a 200-day simple moving average of $4.58.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on NMTC shares. Wall Street Zen raised NeuroOne Medical Technologies to a “sell” rating in a research report on Saturday, February 21st. JonesTrading initiated coverage on NeuroOne Medical Technologies in a research note on Monday, March 2nd. They issued a “buy” rating and a $9.00 price objective for the company. Finally, Zacks Research downgraded NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 13th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $13.50.

Insider Activity at NeuroOne Medical Technologies

In other NeuroOne Medical Technologies news, insider David J. Wambeke bought 166,666 shares of the business’s stock in a transaction dated Sunday, March 1st. The shares were acquired at an average cost of $4.02 per share, with a total value of $669,997.32. Following the acquisition, the insider directly owned 166,666 shares of the company’s stock, valued at $669,997.32. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last 90 days, insiders have sold 2,438 shares of company stock valued at $11,702. Insiders own 11.80% of the company’s stock.

Hedge Funds Weigh In On NeuroOne Medical Technologies

Several institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd increased its position in NeuroOne Medical Technologies by 321.1% in the 4th quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock valued at $65,000 after acquiring an additional 65,163 shares during the period. Squarepoint Ops LLC acquired a new position in NeuroOne Medical Technologies in the 4th quarter valued at about $36,000. Essex Investment Management Co. LLC acquired a new position in NeuroOne Medical Technologies in the 4th quarter valued at about $143,000. Renaissance Technologies LLC increased its position in NeuroOne Medical Technologies by 10.2% in the 4th quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock valued at $578,000 after acquiring an additional 70,428 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in NeuroOne Medical Technologies in the 3rd quarter valued at about $47,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.